
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax is a promising biotechnology company with a strong focus on developing novel vaccines to respond to both known and emerging diseases. With a rich pipeline of high-value assets and potential partnerships, the company has the potential for significant growth and value creation. While there are risks associated with competition and regulatory challenges, Novavax's technology and strong management make it a solid investment opportunity for those with a longer-term outlook.
Bears say
Novavax is facing stiff competition in the crowded market of COVID-19 vaccines, with only a 15% peak penetration projected for its flagship product Nuvaxovid. Even with potentially differentiated tolerability and a strong showing in the 65+ market, the risk of lower market share, combined with a steep decline in COVID-19 vaccine market predicted by experts, leads to a negative outlook for the company's financials, with R&D and SG&A expenses likely to remain high and limited potential for significant revenues from royalties.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares